Avila’s AVL-292 demonstrates disease-modifying effects in prophylactic, medical models of rheumatoid arthritis
Avila Therapeutics™, Inc., a biotechnology institution developing targeted covalent drugs that reception of diseases toe protein silencing, today announced results of preclinical studies demonstrating that its clinical aspirant, AVL-292, potently inhibits B cubicle receptor signaling, and demonstrates efficacy in a rodent replica of rheumatoid arthritis. These different text were presented Saturday, June 26, 2010 at the Coalition of Clinical Immunology Societies (FOCIS) 2010 annual appointment in Boston, MA.
“These results present quite occult disease-modifying effects of AVL-292 in both prophylactic and salutary models of rheumatoid arthritis. In conjunction with the safeness testing Avila Therapeutics has completed, the efficacy details accommodate moving validation in the course of this program as we betterment AVL-292 into clinical studies this year.”
AVL-292 is a novella, orally within reach, covalent stupefy that targetsBruton’s tyrosine kinase (Btk). Barrier of Btk is a heartening fresh modus operandi to treatment of diseases that are driven largely B cells, which are cause of the safe set. AVL-292 bonds selectively and covalently with Btk to shut down a exclude down and restrain its vocation. This special identity theory of functioning confers greater quarry selectivity and a longer duration of motion than is classic of usual poor molecule drugs.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
